SCHEMBL1587633

SCHEMBL1587633

COC(=O)c1ccc(C(=O)NCc2cc(C)n(C)n2)s1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
HTT P42858 3/20 0.58
LMNA P02545 2/20 0.58
HPGD P15428 2/20 0.58
KDM4E B2RXH2 2/20 0.58
USP2 O75604 1/20 0.58
TSHR P16473 1/20 0.58
HSD17B10 Q99714 1/20 0.58
ALOX15 P16050 1/20 0.58
CYP3A4 P08684 1/20 0.47
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
SLC5A7 Q9GZV3 1/20 0.45
ROCK2 O75116 1/20 0.42
POLB P06746 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1587967 0.87 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2HTTLMNAHPGD
SCHEMBL17029122 0.86 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2HTTLMNAHPGD
SCHEMBL13060078 0.82 SMN1; SMN2 (0.64) ALDH1A1SMN1; SMN2HTTLMNAHPGD
SCHEMBL12529458 0.81 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2HTTLMNAHPGD
SCHEMBL1587769 0.76 RAB9A (0.46) ALDH1A1SMN1; SMN2HPGDKDM4ETSHR
SCHEMBL1587971 0.76 KMT2A (0.59) LMNAHPGDTSHR
SCHEMBL2755869 0.75 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2HTTLMNAHPGD
SCHEMBL1587448 0.74 MAPT (0.44) ALDH1A1HPGDTSHRCYP3A4POLB
SCHEMBL1587018 0.73 HPGD (0.67) ALDH1A1SMN1; SMN2HTTLMNAHPGD
SCHEMBL1587443 0.72 SLC40A1 (0.41) LMNAHPGDTSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968542-B2 Thiophene compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2011-06-28 US disclosed
US-20110092496-A1 THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2011-04-21 US disclosed
US-20090118500-A1 THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES, LTD (JP) 2009-05-07 US disclosed
EP-1904472-A1 THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS Nissan Chemical Industries, Ltd. (JP) 2008-04-02 EP disclosed
WO-2007010954-A1 THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118500-A1 THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS TEK, MPL, THPO ALDH1A1 2481/4885SMN1; SMN2 2934/4885HTT 1253/4885
US-20110092496-A1 THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS TEK, MPL, THPO ALDH1A1 2481/4885SMN1; SMN2 2934/4885HTT 1253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.